JP2017521370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017521370A5 JP2017521370A5 JP2016569613A JP2016569613A JP2017521370A5 JP 2017521370 A5 JP2017521370 A5 JP 2017521370A5 JP 2016569613 A JP2016569613 A JP 2016569613A JP 2016569613 A JP2016569613 A JP 2016569613A JP 2017521370 A5 JP2017521370 A5 JP 2017521370A5
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- preparation according
- lyophilized
- nr2b9c
- tat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 6
- 239000004472 Lysine Substances 0.000 claims 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000012931 lyophilized formulation Substances 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 2
- 239000002516 radical scavenger Substances 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- 108010046423 Tat-NR2B9c Proteins 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- XWQVQFBTSBCKLI-FKXNDIMNSA-N dnc008987 Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 XWQVQFBTSBCKLI-FKXNDIMNSA-N 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462004144P | 2014-05-28 | 2014-05-28 | |
| US62/004,144 | 2014-05-28 | ||
| PCT/IB2015/053996 WO2015181757A1 (en) | 2014-05-28 | 2015-05-28 | Lyophilized formulation of tat-nr2b9c with acetylation scavenger |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020087977A Division JP2020143116A (ja) | 2014-05-28 | 2020-05-20 | アセチル化スカベンジャーを含むTat−NR2B9cの凍結乾燥製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017521370A JP2017521370A (ja) | 2017-08-03 |
| JP2017521370A5 true JP2017521370A5 (enExample) | 2018-06-21 |
| JP6707469B2 JP6707469B2 (ja) | 2020-06-10 |
Family
ID=54698211
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569613A Expired - Fee Related JP6707469B2 (ja) | 2014-05-28 | 2015-05-28 | アセチル化スカベンジャーを含むTat−NR2B9cの凍結乾燥製剤 |
| JP2020087977A Pending JP2020143116A (ja) | 2014-05-28 | 2020-05-20 | アセチル化スカベンジャーを含むTat−NR2B9cの凍結乾燥製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020087977A Pending JP2020143116A (ja) | 2014-05-28 | 2020-05-20 | アセチル化スカベンジャーを含むTat−NR2B9cの凍結乾燥製剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10206878B2 (enExample) |
| EP (1) | EP3148568A4 (enExample) |
| JP (2) | JP6707469B2 (enExample) |
| CA (1) | CA2950392A1 (enExample) |
| WO (1) | WO2015181757A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10251935B2 (en) * | 2012-11-28 | 2019-04-09 | Nono Inc. | Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose |
| ES2784500T3 (es) | 2014-05-28 | 2020-09-28 | Nono Inc | Sal de cloruro de Tat-NR2B9c |
| CA2950392A1 (en) | 2014-05-28 | 2015-12-03 | Nono Inc. | Lyophilized formulation of tat-nr2b9c with acetylation scavenger |
| EP4553432A1 (en) | 2023-11-08 | 2025-05-14 | Bachem Holding AG | Drying bag and drying system |
| WO2025099273A1 (en) | 2023-11-08 | 2025-05-15 | Bachem Holding Ag | Drying bag and drying system |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007212147A1 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| MX2008012295A (es) * | 2006-03-28 | 2008-10-09 | Hoffmann La Roche | Formulacion de un anticuerpo monoclonal humano anti-igf-1r. |
| EP1884521A1 (en) | 2006-07-31 | 2008-02-06 | Xigen S.A. | Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| JP2012519712A (ja) * | 2009-03-06 | 2012-08-30 | メディミューン,エルエルシー | ヒト化抗cd19抗体製剤 |
| EP2458990B1 (en) * | 2009-07-28 | 2016-03-30 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| NZ600096A (en) * | 2009-11-20 | 2013-08-30 | Centro Inmunologia Molecular | Formulations of antibody |
| RU2588658C2 (ru) * | 2010-04-27 | 2016-07-10 | ЭсСиАйЭл Текнолоджи ГмбХ | Стабильные водные композиции белка mia/cd-rap |
| EP2616094B1 (en) * | 2010-08-12 | 2017-11-08 | NoNO Inc. | Treatment of penetrative injury to the brain |
| DK2709657T3 (en) * | 2011-05-17 | 2019-01-14 | Soligenix Inc | Thermostable vaccine compositions and methods for their preparation |
| UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| US10251935B2 (en) | 2012-11-28 | 2019-04-09 | Nono Inc. | Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose |
| AU2013352437B2 (en) | 2012-11-28 | 2018-04-12 | Nono Inc. | Lyophilized formulation of TAT-NR2B9c |
| CA2950392A1 (en) | 2014-05-28 | 2015-12-03 | Nono Inc. | Lyophilized formulation of tat-nr2b9c with acetylation scavenger |
| ES2784500T3 (es) | 2014-05-28 | 2020-09-28 | Nono Inc | Sal de cloruro de Tat-NR2B9c |
-
2015
- 2015-05-28 CA CA2950392A patent/CA2950392A1/en active Pending
- 2015-05-28 US US15/313,541 patent/US10206878B2/en active Active
- 2015-05-28 EP EP15800695.7A patent/EP3148568A4/en not_active Withdrawn
- 2015-05-28 WO PCT/IB2015/053996 patent/WO2015181757A1/en not_active Ceased
- 2015-05-28 JP JP2016569613A patent/JP6707469B2/ja not_active Expired - Fee Related
-
2019
- 2019-01-02 US US16/238,355 patent/US20190231693A1/en not_active Abandoned
-
2020
- 2020-05-20 JP JP2020087977A patent/JP2020143116A/ja active Pending
-
2021
- 2021-09-13 US US17/473,568 patent/US20220096383A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017521370A5 (enExample) | ||
| RU2016150678A (ru) | ХЛОРИДНАЯ СОЛЬ ПЕПТИДА TAT-NR2B9с, КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| JP2016520075A5 (enExample) | ||
| JP2015091902A5 (enExample) | ||
| ZA201900367B (en) | Formulation of a peptide vaccine | |
| WO2016184576A3 (en) | Dry powder composition comprising long-chain rna | |
| BR112017009405A2 (pt) | composições antibióticas. | |
| WO2015044337A3 (en) | Dry formulations of vaccines that are room temperature stable | |
| EA201890220A1 (ru) | Вакцина против rsv | |
| JP2013542919A5 (enExample) | ||
| PE20181400A1 (es) | Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab | |
| JP2014000092A5 (enExample) | ||
| PH12014501628A1 (en) | Stabilized formulations containing anti-ang2 antibodies | |
| WO2007035455A3 (en) | Stabilizers for freeze-dried vaccines | |
| PE20190420A1 (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
| JP2018528242A5 (enExample) | ||
| HRP20191166T1 (hr) | Stabilizirani proteini, namijenjeni imuniziranju protiv bakterije staphylococcus aureus | |
| EP4606820A3 (en) | Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents | |
| JP2017532343A5 (enExample) | ||
| AR082257A1 (es) | Composicion de inmunoglobulinas humanas concentradas, procedimiento | |
| HRP20211838T1 (hr) | Krnji protein vp4 rotavirusa i njegova primjena | |
| EA201491513A1 (ru) | Рекомбинантные штаммы escherichia coli | |
| EA202092926A2 (ru) | Лиофилизированные составы, содержащие фактор ix | |
| EA202090536A1 (ru) | Кристаллические формы 3-замещенного 1,2,4-оксадиазола | |
| EA201991023A1 (ru) | Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту |